Search results for: infliximab

Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis

Reuters Staff | May 3, 2016

NEW YORK (Reuters Health)—About two-thirds of patients with ulcerative colitis (UC) had mucosal healing by the end of induction treatment with the infliximab biosimilar CT-P13, according to results of the first prospective study to evaluate this. CT-P13 is the first biosimilar monoclonal antibody of reference infliximab (Remicade) approved in Europe and several other countries where…

Infliximab Biosimilar Receives FDA Approval

Michele B. Kaufman, PharmD, BCGP | April 6, 2016

The FDA has officially approved an infliximab biosimilar for the treatment of multiple autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Prescribing information is now available…

FDA Update: Infliximab Biosimilar Garners Support & Fibromyalgia Drug Receives Fast Track

Michele B. Kaufman, PharmD, BCGP | February 17, 2016

Recently, an FDA committee announced support for the approval of CT-P13, an infliximab biosimilar. The FDA has also fast tracked the development of a fibromyalgia treatment designed for multiple symptoms…

Resunab Fast Tracked to Treat Scleroderma, Plus, Infliximab Biosimilars in Europe

Michele B. Kaufman, PharmD, BCGP | September 2, 2015

The FDA has fast-tracked the development of a drug to treat systemic sclerosis, or scleroderma; initial clinical trials started in June. Also, a major hospital group in France has selected the biosimilar infliximab to treat its patients with RA, Crohn’s disease and psoriasis…

Studies Challenge Conventional Infliximab Protocols in IBD

Laura Newman | July 10, 2015

NEW YORK (Reuters Health)—Dose optimization of infliximab is needed much earlier in ulcerative colitis than in Crohn’s disease, a single-center retrospective study reveals. “We compared the rates of dose increases over a fairly lengthy period of time,” said Dr. Mark Silverberg, the study’s senior author from the Mount Sinai Hospital in Toronto. “Patients with ulcerative…

Biosimilar for Infliximab Launched in Europe

Michele B. Kaufman, PharmD, BCGP | April 1, 2015

Plus, updates on arhalofenate, ALO-02, and other rheumatology drug news, safety information

Infliximab, Tocilizumab Can Help in Large Vessel Vasculitis

Lara C. Pullen, PhD | March 13, 2015

Case studies show some patients with LVV can achieve remission after treatment with biological agents

The Management of Psoriatic Arthritis: A Review

Samantha C. Shapiro, MD | November 17, 2024

WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…

Updates from the ACR Insurance Subcommittee

From the College | November 12, 2024

The ACR Insurance Subcommittee (ISC) of the Committee on Rheumatologic Care has been hard at work, advocating to payers on behalf of the ACR and its members. Following is an update on some of the work this group has been doing to help address concerns about reimbursement and administrative burden, while ensuring continued access to…

AC&R Study Summary: Standardizing Treatment for Moderately Severe JDM

By Matthew A. Sherman, MD, MHSc, & Stacey E. Tarvin, MD, MS | November 10, 2024

Why was this study done? Juvenile dermatomyositis (JDM) is the most common type of idiopathic inflammatory myopathy in childhood, and most patients have a chronic disease course requiring prolonged administration of systemic glucocorticoids and immunosuppressive agents. The initial management for patients with moderately severe JDM is relatively standardized, typically including methotrexate and systemic glucocorticoids with…